- Conditions
- Wet Age Related Macular Degeneration, wAMD
- Interventions
- EYP-1901, Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 70 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 3,154
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Central Nervous System Carcinoma
- Interventions
- Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 137
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- carboplatin, lobradimil
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 152 more
- Conditions
- Parkinson's Disease, Dysphagia, Dysarthria
- Interventions
- Voice/Respiration Treatment, Speech/Articulation Treatment
- Behavioral
- Lead sponsor
- University of Colorado, Boulder
- Other
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2012
- U.S. locations
- 2
- States / cities
- Denver, Colorado • San Antonio, Texas
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Abemaciclib, Erlotinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 54
- States / cities
- Fayetteville, Arkansas • Jonesboro, Arkansas • Duarte, California + 39 more
- Conditions
- Diabetes, Hyperlipidemia, Hypertension, Cardiovascular Disease
- Interventions
- CVRS Intervention
- Behavioral
- Lead sponsor
- Korey Kennelty
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 18
- States / cities
- Gainesville, Florida • Tampa, Florida • Pocatello, Idaho + 14 more
- Conditions
- End Stage Renal Disease
- Interventions
- Triferic
- Drug
- Lead sponsor
- Rockwell Medical Technologies, Inc.
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- Loma Linda, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 5 more
- Conditions
- Prostate Cancer
- Interventions
- Degarelix
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 12
- States / cities
- Anaheim, California • Laguna Woods, California • San Bernardino, California + 9 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 1,014 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 132
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more
- Conditions
- Dermatitis Atopic
- Interventions
- Amlitelimab, Placebo, Tdap vaccine, PPS vaccine
- Drug · Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more
- Conditions
- Solid Tumor, Advanced Solid Tumor
- Interventions
- PYX-201
- Drug
- Lead sponsor
- Pyxis Oncology, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 13 more
- Conditions
- Recurrent Bladder Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage II Bladder Cancer AJCC v6 and v7, Stage III Bladder Cancer AJCC v6 and v7
- Interventions
- Genistein, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Therapeutic Conventional Surgery
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Laguna Hills, California • Iowa City, Iowa + 6 more
- Conditions
- Advanced Solid Tumor
- Interventions
- LDE225, Wafarin, Bupropion
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 13
- States / cities
- Duarte, California • Kansas City, Kansas • Boston, Massachusetts + 9 more
- Conditions
- Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
- Interventions
- asparaginase, daunorubicin hydrochloride, cytarabine, thioguanine, etoposide, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 4 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2021
- U.S. locations
- 88
- States / cities
- Phoenix, Arizona • Downey, California • Long Beach, California + 73 more
- Conditions
- Autoimmune Haemolytic Anaemia
- Interventions
- rilzabrutinib, placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Duarte, California + 23 more
- Conditions
- Periodontal Diseases
- Interventions
- Leukocyte Platelet-rich fibrin, Standard of care OFD
- Procedure · Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Breast Cancer
- Interventions
- Tucatinib in Combination with Palbociclib and Letrozole
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Aurora, Colorado • Chicago, Illinois + 3 more
- Conditions
- Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
- Interventions
- NC410, pembrolizumab
- Drug
- Lead sponsor
- NextCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more
- Conditions
- Multiple Myeloma
- Interventions
- ACY-1215 in combination with pomalidomide and dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 3
- States / cities
- Dallas, Texas • San Antonio, Texas • Salt Lake City, Utah
- Conditions
- Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Conventional Surgery, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Vincristine Sulfate Liposome
- Radiation · Procedure · Drug + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2026
- U.S. locations
- 199
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
- Conditions
- Posttraumatic Stress Disorder (PTSD)
- Interventions
- Shelter Dog Adoption
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Aortic Stenosis
- Interventions
- SAPIEN S3 valve
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,822 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 55
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 46 more
- Conditions
- Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction
- Interventions
- Ketone Monoester (KE)
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Cancer
- Interventions
- docetaxel, NPI-2358 + docetaxel
- Drug
- Lead sponsor
- Nereus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Encinitas, California • San Diego, California + 4 more